Presentation is loading. Please wait.

Presentation is loading. Please wait.

MET Mutation Associated with Responsiveness to Crizotinib

Published byInge Kusnadi Modified over 5 years ago

Similar presentations

Presentation on theme: "MET Mutation Associated with Responsiveness to Crizotinib"— Presentation transcript:

1 MET Mutation Associated with Responsiveness to Crizotinib
Saiama N. Waqar, MD, Daniel Morgensztern, MD  Journal of Thoracic Oncology  Volume 10, Issue 5, Pages e29-e31 (May 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 MET chr7:g G>C alteration as viewed in the Integrative Genomics Viewer (Broad Institute, Cambridge, MA). The guanine to cytosine alteration is highlighted at the terminus of MET exon 14. Journal of Thoracic Oncology  , e29-e31DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 MET alteration and predicted outcomes. Each panel shows MET exon 14 and flanking DNA sequence with splicing events indicated by black lines followed by the resulting protein sequence. A, Normal MET sequence and splicing. The c-Cbl binding site (Y1021) is marked with a box. B, Effect of chr7:g G>C alteration (red, arrow) if splicing is unimpaired resulting in a p.D1028H substitution without deletion of exon 14. C, Alternately, as predicted by splice site algorithms, the variant could result in altered splicing with deletion of exon 14, as has been described for other MET splice site variants in lung cancer. Journal of Thoracic Oncology  , e29-e31DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Radiographic response to crizotinib. CT scans (A) at baseline and (B) after 6 weeks and (C) 6 months of crizotinib. CT, computed tomography. Journal of Thoracic Oncology  , e29-e31DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "MET Mutation Associated with Responsiveness to Crizotinib"

Similar presentations

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.
Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.
Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation  Vienna Ludovini, PhD,

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation  Vienna Ludovini, PhD,
NA  Journal of Thoracic Oncology 

NA  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
The Moth-Eaten Lung Journal of Thoracic Oncology

The Moth-Eaten Lung Journal of Thoracic Oncology
Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.

Similar presentations

Ads by Google